The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2026

Filed:

Aug. 29, 2017
Applicant:

Hackensack University Medical Center, Hackensack, NJ (US);

Inventors:

Yong Zhao, River Edge, NJ (US);

Robert Korngold, Wayne, NJ (US);

Michele Donato, Livingston, NJ (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/071 (2010.01); A61K 35/12 (2015.01); A61K 35/14 (2015.01); A61K 35/15 (2025.01); C12N 5/073 (2010.01); C12N 5/0783 (2010.01); C12N 5/0786 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0692 (2013.01); A61K 35/15 (2013.01); C12N 5/0605 (2013.01); C12N 5/0636 (2013.01); C12N 5/0645 (2013.01); A61K 2035/122 (2013.01); A61K 35/14 (2013.01); C12N 2501/125 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2501/599 (2013.01); C12N 2502/025 (2013.01); C12N 2502/1107 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1157 (2013.01); C12N 2502/1164 (2013.01); C12N 2506/11 (2013.01);
Abstract

The described invention provides a pharmaceutical composition comprising a therapeutic amount of an educated mononuclear cell product, a process for preparing the educated mononuclear cell product, and a method for treating a disease characterized by lymphocyte autoreactivity. Mononuclear cells from a diseased subject are co-cultured with a viable population of adherent umbilical cord blood stem cells at at least 80% confluence to form an educated mononuclear cell product. A therapeutic amount of the educated mononuclear cell product is returned by infusion intravascularly to the subject. The therapeutic amount is effective to modulate autoreactivity in a T cell compartment of the subject and to reduce symptoms of the disease characterized by lymphocyte autoreactivity.


Find Patent Forward Citations

Loading…